Prednisolone metasulfobenzoate sodium controlled-release - Alizyme

Drug Profile

Prednisolone metasulfobenzoate sodium controlled-release - Alizyme

Alternative Names: ATL-2502; COLAL-PRED; TSD-0011

Latest Information Update: 20 Feb 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alizyme
  • Developer Alizyme; Norgine; Prometheus Laboratories; TSD Japan
  • Class Anti-inflammatories; Antiallergics; Antirheumatics; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Ulcerative colitis

Most Recent Events

  • 31 Jul 2011 Prometheus Laboratories has been acquired by Nestle
  • 25 Feb 2011 Suspended - Phase-II for Ulcerative colitis in USA (PO)
  • 20 Dec 2010 No development reported - Phase-I for Ulcerative colitis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top